文献速递帕金森病与运动障碍脑血管病

SIAXI:incobotulinumtoxinA治疗慢性流涎的安慰剂对照随机双盲研究

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
PubMed 文献 · Neurology · 2019-03-27

SIAXI是一项III期随机双盲安慰剂对照研究,纳入184例因帕金森病、非典型帕金森综合征、卒中或创伤性脑损伤所致慢性流涎的成人患者,按2:2:1随机接受安慰剂、incobotulinumtoxinA 75 U或100 U单次治疗。结果显示100 U组第4周非刺激唾液流率及患者总体印象变化量表评分均显著优于安慰剂,疗效持续至第16周,常见治疗相关不良事件为口干和吞咽困难。

要点

  • incobotulinumtoxinA 100 U可显著降低慢性流涎患者第4周非刺激唾液流率。
  • 100 U组第4周患者总体印象变化量表评分显著优于安慰剂,疗效持续至第16周。
  • 常见治疗相关不良事件为口干和吞咽困难,100 U组口干发生率2.7%、吞咽困难0.0%。

核心结论

  • incobotulinumtoxinA 100 U是治疗成人慢性流涎的有效且耐受性良好的方法。

研究设计与样本

  • III期随机双盲安慰剂对照研究,184例成人患者按2:2:1随机接受安慰剂(n=36)、incobotulinumtoxinA 75 U(n=74)或100 U(n=74)单次治疗。

主要发现

  • 100 U组第4周非刺激唾液流率较基线下降,与安慰剂差异显著(p=0.004)。
  • 100 U组第4周患者总体印象变化量表评分改善,与安慰剂差异显著(p=0.002)。
  • 疗效持续至注射后第16周。
  • 75 U组和100 U组最常见治疗相关不良事件分别为口干(5.4%和2.7%)和吞咽困难(2.7%和0.0%)。

临床怎么用

  • 对于因帕金森病、非典型帕金森综合征、卒中或创伤性脑损伤所致慢性流涎的成人患者,可考虑使用incobotulinumtoxinA 100 U单次注射治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic sialorrhea due to Parkinson disease (PD), atypical parkinsonism, stroke, or traumatic brain injury (TBI). METHODS: Adult patients with PD (70.7%), atypical parkinsonism (8.7%), stroke (19.0%), or TBI (2.7%) were randomized (2:2:1) to double-blind treatment with placebo (n = 36), or total doses of incobotulinumtoxinA 75 U (n = 74) or 100 U (n = 74), in a single treatment cycle. The coprimary endpoints were change in unstimulated salivary flow rate from baseline to week 4, and patients' Global Impression of Change Scale score at week 4. Adverse events were recorded throughout. RESULTS: A total of 184 patients were randomized. Both incobotulinumtoxinA dose groups showed reductions in mean unstimulated salivary flow rate at week 4, with a significant difference vs placebo in the incobotulinumtoxinA 100 U group (p = 0.004). Patients' Global Impression of Change Scale scores also improved at week 4, with a significant difference vs placebo in the incobotulinumtoxinA 100 U group (p = 0.002). A lasting effect was observed at week 16 post injection. The most frequent treatment-related adverse events in the incobotulinumtoxinA 75 U and 100 U groups were dry mouth (5.4% and 2.7% of patients) and dysphagia (2.7% and 0.0% of patients). CONCLUSIONS: IncobotulinumtoxinA 100 U is an effective and well-tolerated treatment of chronic sialorrhea in adults. CLINICALTRIALSGOV IDENTIFIER: NCT02091739. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that incobotulinumtoxinA reduces salivary flow rates in patients with chronic sialorrhea due to PD, atypical parkinsonism, stroke, or TBI.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019. PMID: 30918101. doi:10.1212/WNL.0000000000007368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。